久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

瑞士Biocartis 
Biocartis 創(chuàng)立于2007年，是一家私營生物技術(shù)公司。其創(chuàng)始人為魯?shù)?鮑威爾博士、菲利浦.雷諾教授和內(nèi)德.東澤爾。Biocartis 致力于開發(fā)新診斷技術(shù)平臺(tái)，為不同復(fù)雜程度的分子生物指標(biāo)檢測服務(wù)。公司計(jì)劃于2012年將多功能及精巧分子診斷平臺(tái)推向市場。該平臺(tái)操作簡便，將降低分子診斷測試的準(zhǔn)入壁壘。它位于瑞士洛桑聯(lián)邦理工大學(xué)的科技園以及荷蘭埃因霍溫技術(shù)學(xué)院內(nèi)。

公司自2009年以來獲得了來自一些財(cái)團(tuán)的巨額投資， 其中包括一些歐洲最成功的生物公司企業(yè)家投資，例如Aescap風(fēng)險(xiǎn)管理、Advent 風(fēng)險(xiǎn)投資公司、Biovest, Bebiopharm 集團(tuán)以及KBC私募基金公司和Johnson & Johnson開發(fā)公司。

Biocartis aims to transform the global diagnostics market by making personalized medicine an everyday reality. The challenge Biocartis addresses is to enable the broadest possible access to new technologies that will allow individual diagnoses to be made quickly based on a systematic analysis of the wealth of rapidly emerging biomarkers rather than solely on physiological symptoms as they are today. Ending the ‘one drug fits all’ paradigm will empower physicians to make better diagnoses based on better information leading to better treatment outcomes and the more efficient use of precious healthcare resources.

Biocartis intends to become a fully integrated provider of novel, broadly applicable molecular diagnostics and immunodiagnostics solutions (instruments, analytical techniques, chemistries, sample preparation and other innovative tools) with high-value clinical assay menus. These solutions are designed to be compatible with deployment in a wide variety of health care settings, providing rapid, high-quality care close to the patient. Biocartis’ vision is shared by its current collaborators which include bioMérieux and Janssen Pharmaceutica (J&J).
Biocartis is currently developing two innovative systems that share a common user interface and design philosophy:

A Molecular Diagnostics Platform system is designed for the MDx market, comprising an instrument, communication console and single use, disposable cartridges. This system can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with truly minimal user intervention.
A Multiplex Detection Platform that has been built around disposable, microfluidic cartridges with digitally encoded microparticles for the rapid and sensitive detection of a broad range and number of biomarkers. The first product from this technology will focus on protein-based biomarkers and will allow Biocartis to enter the immunoassay market.
Biocartis was founded in 2007 by Dr. Rudi Pauwels (Co-founder of Tibotec, Virco and Galapagos Genomics), Prof. Philippe Renaud (Prof. at EPFL), and Nader Donzel (Co-founder of Scitec laboratory Automation). The company has raised more than €100 million in equity funding.
Biocartis SA is based at the EPFL's Innovation Square in Lausanne, Switzerland; it has a fully owned Belgian subsidiary in Mechelen and a Dutch subsidiary at the High Tech Campus in Eindhoven.